Geron’s mission is rooted in Nobel Prize – winning discoveries, but the challenge wasn’t the science — it was how to clearly tell that story as the company brought a new product to market.
The work started in ambiguity. Geron needed a single experience that could speak to investors, partners, and future talent, while accurately reflecting complex science, manufacturing, and clinical progress. There wasn’t a clear model to follow, and different teams had different ideas of what the site needed to be.
Working closely with leadership and cross-functional partners, we aligned on a clear direction for the experience and what it needed to communicate. From there, I helped shape an editorial-driven website that could flex across audiences — showcasing the pipeline, manufacturing capabilities, people, and progress in a way that felt focused and intentional.
I stayed hands-on throughout the work, guiding UX, brand, typography, and tone to better reflect Geron’s bold character, while also designing custom graphics to make complex information easier to understand. Those same systems extended into key industry moments, supporting launches and events designed to build awareness and engagement.
The result was a clearer, more confident digital foundation that helped Geron bring their story to market — one that teams could rally around and evolve as the company moved forward.
FDA approved RYTELO on June 6, 2024









Animation was designed to explain how Telomerase operates in the bloodstream. The final video was used to showcase these advancements to investors, and the media, as well as event experiences. R&D Pipeline was reimagined to smoothly flow between the desktop, tablets, and mobile.

